Analysts at B. Riley Reconfirmed their Past ‘Buy’ rating on Shares Adamis Pharmaceuticals (NASDAQ:ADMP), Set a $6.25 Target Price per Share

March 23, 2018 - By Nellie Frank

 Analysts at B. Riley Reconfirmed their Past ‘Buy’ rating on Shares Adamis Pharmaceuticals (NASDAQ:ADMP), Set a $6.25 Target Price per Share

Adamis Pharmaceuticals (NASDAQ:ADMP) Rating Reaffirmed

New York: In analysts report revealed to clients on Friday morning, B. Riley reconfirmed their Buy rating on Adamis Pharmaceuticals (NASDAQ:ADMP) shares. They now have a $6.25 price target on the firm. B. Riley’s target means a potential upside of 78.57 % from the company’s last stock close.

Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) Ratings Coverage

Among 4 analysts covering Adamis Pharma (NASDAQ:ADMP), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Adamis Pharma has $16 highest and $5 lowest target. $8.94’s average target is 155.43% above currents $3.5 stock price. Adamis Pharma had 10 analyst reports since December 1, 2015 according to SRatingsIntel. Maxim Group maintained Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) rating on Thursday, July 21. Maxim Group has “Buy” rating and $10 target. The rating was maintained by Maxim Group on Monday, August 21 with “Buy”. On Tuesday, September 12 the stock rating was initiated by Raymond James with “Buy”. The firm has “Buy” rating by Raymond James given on Monday, December 4. Maxim Group initiated it with “Buy” rating and $16 target in Tuesday, December 1 report. The stock of Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) has “Buy” rating given on Monday, June 12 by Maxim Group. B. Riley & Co maintained Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) on Friday, March 23 with “Buy” rating.

It closed at $3.5 lastly. It is down 52.09% since March 23, 2017 and is downtrending. It has underperformed by 68.79% the S&P500.

Analysts await Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) to report earnings on March, 29.

Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company has market cap of $116.86 million. The company's specialty pharmaceutical product candidates comprise Epinephrine Injection pre-filled syringe for use in the emergency treatment of acute allergic reactions, including anaphylaxis; dry powder inhaler products consisting of albuterol (APC-2000) and fluticasone (APC-4000) for the treatment of bronchospasm and asthma; and beclomethasone (APC-1000), a metered dose inhaler product for the asthma, as well as APC-1000 and APC-5000 for the treatment of asthma and chronic obstructive pulmonary disease. It currently has negative earnings. It also operates a 503B drug outsourcing facility that provides prescription compounded medications to patients, physician clinics, hospitals, surgery centers, and other clients in the United States.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.